Published in Breast Cancer Res on January 09, 2015
Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J Cancer (2016) 0.80
Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget (2016) 0.78
The role and indications of aggressive locoregional therapy in metastatic inflammatory breast cancer. Sci Rep (2016) 0.75
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol (2012) 4.44
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol (2010) 2.94
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am (2003) 2.82
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol (2014) 2.73
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res (2000) 2.48
Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin (2010) 2.45
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst (2014) 2.28
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res (2008) 2.16
Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res (2000) 2.13
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. Lancet Oncol (2012) 1.91
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol (2009) 1.71
Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. Clin Breast Cancer (2007) 1.70
Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Cancer (2008) 1.63
Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res (2004) 1.59
Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol (1997) 1.58
Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. Cancer (2007) 1.56
Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol (2009) 1.51
The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. Am J Pathol (2008) 1.49
Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res (2011) 1.48
Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat (2012) 1.47
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat (2013) 1.38
Update on the management of inflammatory breast cancer. Oncologist (2003) 1.36
Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer (2003) 1.33
HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat (2008) 1.28
Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol (2009) 1.19
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes. Ann Oncol (2013) 1.14
High incidence of HER-2 positivity in inflammatory breast cancer. Breast (2004) 1.05
Clinical aspects of inflammatory breast cancer. Breast Dis (2006) 1.03
Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer (2013) 1.00
Circulating tumor cells in metastatic inflammatory breast cancer. Ann Oncol (2009) 0.93
Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. Breast J (2010) 0.89
Genomic and expression analysis of microdissected inflammatory breast cancer. Breast Cancer Res Treat (2013) 0.82
Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy. Breast Dis (2006) 0.82
Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. Cancer (2004) 0.80